Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19

Article activity feed

1. Version published to 10.3390/v13040651

   Apr 9, 2021
2. 

   Version published to 10.1101/2020.02.25.965582v3 on bioRxiv

   Nov 27, 2020
3. 

   ScreenIT

   Jun 4, 2020

   SciScore for 10.1101/2020.02.25.965582: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   MERS-CoV infection was detected using rabbit anti-MERS-CoV S antibodies, and cell viability was evaluated by Hoechst 33342 staining.	anti-MERS-CoV S suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Calu-3 cells (ATCC HTB-55; Manassas, VA, USA) were maintained at 37°C with 5% CO2 in Eagle’s Minimum Essential Medium (ATCC, Manassas, VA, USA) with 10% heat-inactivated fetal bovine serum and 1X antibiotic-antimycotic solution (Gibco/Thermo Fisher …

   SciScore for 10.1101/2020.02.25.965582: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   MERS-CoV infection was detected using rabbit anti-MERS-CoV S antibodies, and cell viability was evaluated by Hoechst 33342 staining.	anti-MERS-CoV S suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Calu-3 cells (ATCC HTB-55; Manassas, VA, USA) were maintained at 37°C with 5% CO2 in Eagle’s Minimum Essential Medium (ATCC, Manassas, VA, USA) with 10% heat-inactivated fetal bovine serum and 1X antibiotic-antimycotic solution (Gibco/Thermo Fisher Scientific, Waltham, MA, USA).	Calu-3 suggested: ATCC Cat# HTB-55, RRID:CVCL_0609)
   Viral titers were determined by plaque assays in Vero cells as described [16].	Vero suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)
   Briefly, the virus was amplified in Vero-E6 cells incubated in DMEM containing Pen/Strep and 0.2% bovine serum albumin.	Vero-E6 suggested: None
   Software and Algorithms
   Sentences	Resources
   2.5 Pharmacological action clustering: The information regarding pharmacological actions of each compound was compiled by using ChemIDPlus and MESH databases [20,21] and information provided by the vendors.	MESH suggested: (MeSH, RRID:SCR_004750)
   The information on approval status for drugs was retrieved from DrugBank, version 5.0.7 [22].	DrugBank suggested: (DrugBank, RRID:SCR_002700)
   The expected responses were calculated based on the zero interaction potency (ZIP) reference model using SynergyFinder version 2 [17].	SynergyFinder suggested: (SynergyFinder, RRID:SCR_019318)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).

   ---

   Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 23. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
4. 

   Version published to 10.1101/2020.02.25.965582v2 on bioRxiv

   Mar 19, 2020
5. 

   Version published to 10.1101/2020.02.25.965582v1 on bioRxiv

   Mar 2, 2020